Glucagon-Like Peptide-1 Triggers Protective Pathways in Pancreatic Beta-Cells Exposed to Glycated Serum
Advanced glycation end products (AGEs) might play a pathophysiological role in the development of diabetes and its complications. AGEs negatively affect pancreatic beta-cell function and the expression of transcriptional factors regulating insulin gene. Glucagon-like peptide-1 (GLP-1), an incretin h...
Saved in:
Main Authors: | Alessandra Puddu, Roberta Sanguineti, Arianna Durante, Alessio Nencioni, François Mach, Fabrizio Montecucco, Giorgio L. Viviani |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2013-01-01
|
Series: | Mediators of Inflammation |
Online Access: | http://dx.doi.org/10.1155/2013/317120 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
An Emerging Role of Glucagon-Like Peptide-1 in Preventing Advanced-Glycation-End-Product-Mediated Damages in Diabetes
by: Alessandra Puddu, et al.
Published: (2013-01-01) -
Effects of High Glucose Levels and Glycated Serum on GIP Responsiveness in the Pancreatic Beta Cell Line HIT-T15
by: Alessandra Puddu, et al.
Published: (2015-01-01) -
Advanced Glycation End Products Play Adverse Proinflammatory Activities in Osteoporosis
by: Roberta Sanguineti, et al.
Published: (2014-01-01) -
Evidence for the Gut Microbiota Short-Chain Fatty Acids as Key Pathophysiological Molecules Improving Diabetes
by: Alessandra Puddu, et al.
Published: (2014-01-01) -
Advanced Glycation End-Products and Hyperglycemia Increase Angiopoietin-2 Production by Impairing Angiopoietin-1-Tie-2 System
by: Alessandra Puddu, et al.
Published: (2019-01-01)